Edgewise Therapeutics Stock Gains Momentum on Clinical Progress

Shares of Edgewise Therapeutics saw significant upward movement in today’s trading session, closing at $15.57 for a notable gain of 6.50%. This advance positions the biotech firm’s stock well above its previous closing price of $14.67 and represents a substantial 46.89% increase from its 52-week low of $10.60, recorded in April.

The company’s second-quarter 2025 financial results revealed a net loss of $36.1 million, or $0.34 per share. This performance exceeded analyst expectations of a $0.41 per share loss by 17.91%. Edgewise demonstrated marked improvement compared to the first quarter of 2025, when it reported a net loss of $40.8 million.

Key financial metrics for Q2 2025 include:
* Net loss: $36.1 million ($0.34 per share)
* Research and development expenses: $33.6 million (down from $36.8 million in Q1)
*... Read more...